Improvement of blood glucose control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg.
The initial dose of this medicine should be based on the patient's current treatment regimen.
1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy:
The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, and gradually adjust the dose after evaluating the adequacy of the treatment response.
2. Patients switching from combination therapy with pioglitazone and metformin:
Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their previous doses of pioglitazone and metformin.
3. Patients with renal impairment: All dosage adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this medicine.
After administering this medicine to a patient or increasing the dose, monitor carefully for adverse reactions associated with fluid retention.
This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin.
Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.
Improvement of blood glucose control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is designed to assist patients with type 2 diabetes in controlling their blood sugar levels. It works in conjunction with dietary and exercise regimens, using a combination of pioglitazone and metformin to effectively lower and manage blood sugar. This enables stable management of blood sugar levels, contributing to the prevention of complications. Thus, using this medication as part of a systematic treatment plan can be very helpful in blood sugar control.
Dosage and Administration
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg.
The initial dose of this medicine should be based on the patient's current treatment regimen.
1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy:
The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, and gradually adjust the dose after evaluating the adequacy of the treatment response.
2. Patients switching from combination therapy with pioglitazone and metformin:
Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their previous doses of pioglitazone and metformin.
3. Patients with renal impairment: All dosage adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this medicine.
After administering this medicine to a patient or increasing the dose, monitor carefully for adverse reactions associated with fluid retention.
This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin.
Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.
Precautions
This medication helps regulate blood sugar levels for patients with type 2 diabetes, and the two components work together to lower blood sugar.
When taking this medication, it is essential to confirm that kidney function is normal, as it is safest not to use it if kidney function is impaired.
Patients with abnormal liver function or liver disease should consult a physician before taking this medication and should undergo regular liver function tests.
Patients with heart disease or heart failure need to be cautious when using this medication, and especially those with severe heart failure should not start taking it.
This medication can cause a rare but serious side effect known as lactic acidosis, so if symptoms such as malaise, muscle pain, difficulty breathing, or abdominal pain occur, it is crucial to inform a doctor immediately.
Alcohol consumption may increase the risk of side effects from this medication, so excessive drinking should be avoided while taking it.
Women who are pregnant or may become pregnant, as well as breastfeeding women, are advised not to take this medication.
During treatment with this medication, regular checks of blood sugar, kidney function, liver function, and hematological tests should be conducted to monitor for any abnormalities.
There may be interactions with other drugs, so anyone taking other medications should inform their doctor or pharmacist, especially if taking drugs that could affect kidney function.
In case of overdose, it is crucial to visit a medical facility for appropriate treatment, and if necessary, dialysis may be performed to remove the medication.
This medication has not been proven safe and effective for children, so it is not used in pediatric patients.
Elderly patients are likely to have reduced kidney function, so initial and maintenance doses should be determined with caution, and kidney function should be frequently evaluated.
Weight gain, edema, and symptoms of heart failure may occur during treatment with this medication, so it is important to consult healthcare providers if these symptoms arise.
While taking this medication, it is important to maintain regular meals and exercise and to continually monitor blood sugar control.
Side effects
Lactic acidosis
hypoglycemia
fatigue
myalgia
dyspnea
asthenia
abdominal pain
hypothermia
hypotension
resistant bradyarrhythmia
Show 40 moreCollapse
congestive heart failure
excessive and rapid weight change
dyspnea
edema
upper respiratory infection
diarrhea
complex edema
peripheral edema
headache
urinary tract infection
sinusitis
dizziness
lower limb edema
weight gain
myalgia
dental disorders
worsening of diabetes
pharyngitis
anemia
elevated ALT
elevated CPK
decreased vision
diabetic macular edema
liver failure
edema
fluid retention
volume-related cases
gross hematuria
urinary disorders
urgency
dyspepsia
insomnia
dry mouth
constipation
abdominal distension
gastroesophageal reflux disease
intestinal aeropathy
increased serum creatinine
increased blood urea
fractures
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Ideally, it should be stored at room temperature, between 1 degree and 30 degrees.
Appearance and packaging
Appearance
White to grayish-white, oblong, convex film-coated tablets
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.